Publications by authors named "Diego Malon Gimenez"
The incidence of melanoma among young adults has risen, yet mortality has declined annually since the introduction of immune checkpoint inhibitors (ICI). The utilization of peri-operative ICI has significantly altered the treatment landscape in melanoma, with PD-1 inhibitors showing promising efficacy in improving relapse-free survival rates in high-risk stage II-III disease. With the increasing use of ICI, secondary concerns have emerged regarding the impact of cancer drugs on fertility and reproductive health among women of childbearing potential, especially in early-stage cancer settings.
View Article and Find Full Text PDFArticle Synopsis
- Researchers are focusing on the need for biomarkers to enhance the use of pertuzumab in treating early-stage ERBB2-positive breast cancer, moving beyond just ERBB2 status.
- The study aims to evaluate if the HER2DX genomic assay can predict patient responses to trastuzumab-based chemotherapy, with or without pertuzumab, using tissue samples taken before treatment.
- In a retrospective analysis involving 155 patients, the study found significant associations between baseline pCR scores from the genomic assay and the likelihood of achieving a pathologic complete response in breast and axillary tissues.